TYRA
HealthcareTyra Biosciences, Inc.
$26.29
$-0.50 (-1.87%)
Jan 5, 2026
Price History (1Y)
Analysis
Tyra Biosciences, Inc. is a biotechnology company in the healthcare sector with approximately 60 employees. The company has a market capitalization of $1.40B and operates within the broader biotechnology industry. The company's financial health is marked by significant losses, with net income totaling -$111,684,000 over the trailing twelve months. EBITDA and free cash flow are also negative at -$125,432,000 and -$48,557,752, respectively. Cash reserves amount to $274.92M, while debt totals $5.92M. Profitability metrics, including gross margin, operating margin, and profit margin, are all 0.0%. Returns on equity and assets are -34.7% and -23.1%, respectively. The company's valuation context is characterized by a negative forward P/E ratio of -12.04 and an EV/EBITDA ratio of -9.26. The price to book ratio stands at 5.00, indicating a higher valuation compared to the company's net asset value. Beta is 1.07, suggesting that the stock may be more volatile than the market as a whole.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Visit website →Key Statistics
- Market Cap
- $1.40B
- P/E Ratio
- N/A
- 52-Week High
- $27.66
- 52-Week Low
- $6.42
- Avg Volume
- 419.90K
- Beta
- 1.07
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 60